0001104659-13-034200.txt : 20130429 0001104659-13-034200.hdr.sgml : 20130427 20130429160528 ACCESSION NUMBER: 0001104659-13-034200 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130424 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20130429 DATE AS OF CHANGE: 20130429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERAVANCE INC CENTRAL INDEX KEY: 0001080014 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943265960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30319 FILM NUMBER: 13791700 BUSINESS ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508086000 MAIL ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: S. SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICINE INC DATE OF NAME CHANGE: 20000302 8-K 1 a13-10598_28k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 


 

FORM 8-K

 


 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): April 24, 2013

 


 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware

(State or Other Jurisdiction of
Incorporation)

 

000-30319

(Commission File Number)

 

94-3265960

(I.R.S. Employer Identification Number)

 

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

(a)                                 The Annual Meeting of Stockholders of the Company was held on April 24, 2013.

 

(b)                                 The nominees listed below were elected directors with the respective votes set forth opposite their names:

 

 

 

Votes for

 

Votes withheld

 

Rick E Winningham

 

87,135,110

 

1,915,103

 

Henrietta Holsman Fore

 

87,138,123

 

1,912,090

 

Robert V. Gunderson, Jr.

 

86,490,856

 

2,559,357

 

Arnold J. Levine. Ph.D.

 

87,185,506

 

1,864,707

 

Burton G. Malkiel, Ph.D.

 

87,197,908

 

1,852,305

 

Peter S. Ringrose, Ph.D.

 

87,195,298

 

1,854,915

 

William H. Waltrip

 

87,169,118

 

1,881,095

 

George M. Whitesides, Ph.D.

 

87,167,921

 

1,882,292

 

William D. Young

 

87,169,348

 

1,880,865

 

 

In a non-binding advisory vote, the stockholders voted to approve the compensation of the Company’s named executive officers disclosed in the Company’s 2013 proxy statement.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

88,714,953

 

254,724

 

80,536

 

 

The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

94,498,719

 

324,439

 

36,129

 

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

THERAVANCE, INC.

 

 

 

 

Dated: April 29, 2013

By:

/s/ Michael W. Aguiar

 

 

Michael W. Aguiar

 

 

Chief Financial Officer

 

3